Imiquimod in cutaneous oncology;Imiquimod en oncología cutánea

Dermatologia Revista Mexicana

Volumn 53, Issue 4, 2009, Pages 167-172

  García, Carlos ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Actynic keratosis; Effectiveness; Imiquimod

Indexed keywords

FLUOROURACIL; IMIQUIMOD; LIQUID NITROGEN; PLACEBO;

ACTINIC KERATOSIS; ARTICLE; BASAL CELL CARCINOMA; BOWEN DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CRYOTHERAPY; DRUG EFFICACY; HISTOPATHOLOGY; HUMAN; MALIGNANT LENTIGO; RANDOMIZED CONTROLLED TRIAL; SKIN CARCINOMA; SPINOCELLULAR CARCINOMA; TREATMENT DURATION;

EID: 70249106705     PISSN: 01854038     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Matthew E. Falagas, Anna G. Angelousi, Peppas G. Imiquimod for the treatment of actinic keratosis: A meta-analysis of randomized controlled trials. J Am Acad Dermatol 2006;55(3):537-538 (Pubitemid 44189601)
2. Hadley G, Derry S, Moore RA. Imiquimod for actinic keratosis: systematic review and meta-analysis. J Invest Dermatol 2006;126(6):1251-1255 (Pubitemid 43997904)
3. Ferrándiz C. Update on actinic keratosis in clinical trial experience with imiquimod. Br J Dermatol 2007;157(Suppl. 2):32-33. (Pubitemid 350179627)
4. Krawtchenko N, Roewert-Huber J, Ulrico M, Mann M, et al. Randomised study of topical 5% imiquimod vs topical 5-fluorouracil vs cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol 2007;157(Suppl. 2):34-40.
5. Ulrico C, Bichel J, Euvrard S, Guido B, et al. Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. Br J Dermatol 2007;157(Suppl. 2):25-31. (Pubitemid 350179626)
6. Jorizzo J, Dinehart S, Matheson R, Moore JK, et al. Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. J Am Acad Dermatol 2007;57(2):265-268 (Pubitemid 47048863)
7. Alomar A, Bichel J, McRae S. Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head. Br J Dermatol 2007;157(1):133-141 (Pubitemid 46934262)
8. Zeichner JA, Stern DW, Uliasz A, Itenberg S, Lebwohl M. Placebo-controlled, double- blind, randomized pilot study of imiquimod 5% cream applied once a week for 6 months for the treatment of actinic keratoses. J Am Acad Dermatol 2009;60(1):59-62.
9. Geisse J, Caro I, Lindholm J, Golitz L, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 2004;50(5):722-733 (Pubitemid 38580549)
10. Oldfield V, Keating GM, Perry GM. Imiquimod: in superficial basal cell carcinoma. Am J Clin Dermatol 2005;6(3):195-200. (Pubitemid 40994262)
11. Schulze HJ, Cribier B, Requena L, Reifenberger J, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol 2005;152(5):939-947 (Pubitemid 40704934)
12. Quirk C, Gebauer K, Owens M, Stampone P. Two-year interim results from a 5-year study evaluating clinical recurrence of superficial basal cell carcinoma after treatment with imiquimod 5% cream daily for 6 weeks. Australas J Dermatol 2006;47(4):258-265 (Pubitemid 44536221)
13. Neville JA, Williford PM, Jorizzo JL. Pilot study using topical imiquimod 5% cream in the treatment of nodular basal cell carcinoma after initial treatment with curettage. J Drugs Dermatol 2007;6(5):507-513
14. Ezughah F, Dawe R, Ibbotson S, Fleming C. A randomized parallel study to assess the safety and efficacy of two different dosing regimens of 5% imiquimod in the treatment of superficial basal cell carcinoma. J Dermatol Ther 2008;19(2):111-117 (Pubitemid 351891551)
15. Ezughah F, Affleck A, Evans A, Ibbotson SH, Fleming CJ. Confirmation of histological clearance of superficial basal cell carcinoma with multiple serial sectioning and Mohs' micrographic surgery following treatment with imiquimod 5% cream. J Dermatol Ther 2008;19(3):156-158 (Pubitemid 351882996)
16. Gollnick H, Barona CG, Frank RG, Ruzicka T, et al. Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe. Eur J Dermatol 2008;18(6):677-682
17. Eigentler TK, Kamin A, Weide BM, Breuninger H, et al. A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low- risk nodular basal cell carcinoma. J Am Acad Dermatol 2007;57(4):616-621 (Pubitemid 47384927)
18. Vidal D, Matías-Guiu X, Alomar A. Fifty-five basal cell carcinomas treated with topical imiquimod: outcome at 5-year follow-up. Arch Dermatol 2007;143:266-268 (Pubitemid 46294599)
19. Ferreres JR, Macaya A, Jucglà A, Muniesa C, et al. Hundreds of basal cell carcinomas in a Gorlin-Goltz syndrome patient cured with imiquimod 5% cream. J Eur Acad Dermatol Venereol 2006;20(7):877-878 (Pubitemid 44102928)
20. Weisberg NK, Varghese M. Therapeutic response of a brother and sister with xeroderma pigmentosum to imiquimod 5% cream. Dermaol Surg 2002;28(6):518-523 (Pubitemid 34686639)
21. Wu JK, Oh C, Strutton G, Siller G. An open-label, pilot study examining the efficacy of curettage followed by imiquimod 5% cream for the treatment of primary nodular basal cell carcinoma. Australas J Dermatol 2006;47(1):46-48.
22. Neville JA, Williford PM, Jorizzo JL. Pilot study using topical imiquimod 5% cream in the treatment of nodular basal cell carcinoma after initial treatment with curettage. J Drugs Dermatol 2007;6(9):910-914
23. Rigel DS, Torres AM, Ely H. Imiquimod 5% cream following curettage without electrodesiccation for basal cell carcinoma: preliminary report. J Drugs Dermatol 2008;7(Suppl. 1):S15-S16.
24. Tillman DK, Carroll MT. A 36-month clinical experience of the effectiveness of curettage and imiquimod 5% cream in the treatment of basal cell carcinoma. J Drugs Dermatol 2008;7(Suppl. 1):S7-S14.
25. Butler DF, Parekh PK, Lenis L. Imiquimod 5% cream as adjunctive therapy for primary, solitary, nodular nasal basal cell carcinomas before Mohs micrographic surgery: a randomized, double blind, vehicle-controlled study. Dermatol Surg 2009;35(1):24-29.
26. Patel GK, Goodwin R, Charla M, Laider P, et al. Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen's disease): a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2006;54(6):1025-1032
27. Rajpar SF, Mariden JR. Imiquimod in the treatment of lentigo maligna. Br J Dermatol 2006;155(4):653-656
28. Cotter MA, McKenna JK, Bowen GM. Treatment of lentigo maligna with imiquimod before staged excision. Dermatol Surg 2008;34(2):147-151
29. Mahoney MH, Joseph MG, Temple C. Topical imiquimod therapy for lentigo maligna. Ann Plast Surg 2008;61(4):419-424